(Before It's News)
PCameron Reynolds, chief executive at blood-based diagnostic tests company VolitionRx (NYSEMKT:VNRX), discusses the group’s full-year results with Proactive Investors.
Story by ProactiveInvestors
Register
Newsletter
If you really want to ban this commenter, please write down the reason: